Drug Trial Radar · NCT07051187
A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Sep 1, 2027
Study completion Sep 1, 2031
Sponsor
- Lead sponsor
- Jiyan LiuAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- West China Hospital
- First posted
- Jul 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Existing nucleoside analogues (NAs) and interferon therapy for chronic hepatitis B (CHB) have limitations, including drug resistance, low HBsAg clearance rates, and irreversible immunosuppression. Therapeutic vaccines, by activating virus-specific T cells and B cells, hold promise for achieving functional cure (HBsAg clearance + sustained HBV DNA negativity). This study is an open-label, single-arm, dose-escalation Phase I clinical trial. The study population consists of patients with chronic hepatitis B virus infection who have achieved virological stability following standard antiviral therapy. Phase I (dose exploration): three dose groups, with three patients per group. The primary objective is to observe and evaluate the safety of the WGc0201 vaccine in the study population (incidence and severity of adverse events).
Conditions
- Chronic Hepatitis B Virus (Hbv)
Interventions
WGc0201Drug
Wgc0201 will be administered by intramuscular route, with a total of 9 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.